Social media at medical congresses
The American Society of Hematology (ASH) Annual Congress dedicated a special-interest session on social media in 2016, called ‘Social Media and Clinical Trials: Physicians, Pharma and Patients‘. The...
View ArticleWhen radiation therapy causes heart disease
It has been known for almost a century that thoracic radiotherapy can cause damage to the heart.[2] However, the first study suggesting that this damage may play an important role in patient outcomes...
View ArticleESMO 2017
Are you ready for ESMO 2017? The Video Journal of Oncology is excited to be attending the ESMO 2017 Congress in Madrid, Spain this September! We have an excellent line-up of interviews scheduled with...
View ArticleFDA Approves Bevacizumab Biosimilar
Bevacizumab-bvzr (Zirabev; Pfizer), a biosimilar to bevacizumab (Avastin; Genentech) has been given the go-ahead by the FDA for five indications. Bevacizumab-bvzr will be used for the treatment of...
View ArticleAll.Can: a world-first survey into cancer care inefficiencies
Completed by a total of 3,981 cancer patients across 10 countries, All.Can is the biggest survey of its kind aiming to highlight and improve patient-reported inefficiencies in cancer care. During an...
View ArticleWorld first in bladder cancer with FDA approval of erdafitinib
Following the release of trial data, the FDA has approved erdafitinib for the treatment of adult patients with fibroblast growth factor receptor 3 (FGFR3) altered metastatic urothelial cancer that has...
View ArticleNHS approval for ovarian cancer drug, olaparib
Olaparib, a maintenance therapy for ovarian cancer, may prolong the benefit of initial treatment in BRCA1/2 mutated ovarian cancer patients who had a complete or partial clinical response after...
View ArticleFurther positive data published for lung cancer screening
The early detection of lung cancer is an exciting field with the potential to greatly improve patient survival. The topic of screening dominates the agenda in this area. Highly anticipated data from...
View ArticleKiller T-cell discovery at Cardiff
Cellular therapies are an exciting area in cancer research and clinical trials. The most widely known, CAR T-cell therapy, has had two product approvals in the hematological oncology space. CAR-T...
View ArticleDarolutamide gets the OK in Europe for nmCRPC
Metastatic castration-resistant prostate cancer (mCRPC) has limited treatment options and metastatic growth is associated with increased comorbidities. To put the size of this group into context,...
View ArticlePositive TAPUR data in advanced CRC presented at GI Cancer Symposium
The 2020 Gastrointestinal (GI) Cancers Symposium presented the latest data in the field, including findings from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. TAPUR, the first...
View ArticleFDA accepts subcutaneous combination of pertuzumab and trastuzumab for HER2+...
Breast cancer is the most common type of malignancy in women.1 Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–25% of breast cancers worldwide and is of great...
View ArticleCAR T-cell therapy guided by scorpion toxin for glioblastoma
The first chimeric antigen receptor T-cell (CAR T-cell) therapy using chlorotoxin (CLTX), a toxin found in the venom of scorpions, demonstrated antitumor activity in a preclinical study recently...
View ArticleNICE response to COVID-19 infection – delivery of systemic anticancer treatments
In light of the ongoing COVID-19 pandemic, the National Institute for Health and Care Excellence (NICE) have put together a rapid guideline on the delivery of systemic anticancer treatments.1 The...
View ArticleUse of pembrolizumab in patients with PS2 NSCLC
Clinical trials assessing the efficacy of pembrolizumab have previously enrolled patients with performance status (PS) 0–1. However, almost a fifth of patients with non-small cell lung cancer (NSCLC)...
View ArticleERAS protocols for breast cancer patients: safe and feasible outpatient...
The Enhanced Recovery After Surgery (ERAS) approach was initially pioneered for colorectal surgery by a group of surgeons in northern Europe, and the principles have since spread across the world and...
View ArticleMulti-cancer detection and localization for more than 50 cancer types
The early detection of cancer improves outcomes for patients – in terms of both reducing treatment burden and improving the chances of a cure. Screening programs are used for many common cancer types...
View ArticleFDA gives mitomycin gel green light for low-grade upper tract urothelial cancer
April 15th saw the Food and Drug Administration (FDA) approval of mitomycin gel (Jelmyto) for the treatment of low-grade upper tract urothelial cancer. The approval was based on the Phase III OLYMPUS...
View ArticleSig3 mutation and immune score determine responses to combination PARP and...
Immune checkpoint inhibitors have shown promising therapeutic outcomes in many types of cancer, but ovarian cancer has been an exception. Thus, developing new strategies to improve the efficacy of...
View ArticleClik here to view.
FDA approve tucatinib for advanced unresectable or metastatic HER2-positive...
Seattle Genetics have announced the U.S. Food and Drug Administration (FDA) have granted approval for tucatinib in combination with trastuzumab and capecitabine for adult patients with advanced...
View ArticleTP53 mutations predict sensitivity to adjuvant chemotherapy in pancreatic...
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive gastrointestinal malignancy and is often associated with a poor prognosis. Surgery remains the only treatment modality for PDAC that is...
View ArticleADAURA: osimertinib demonstrates significant clinical benefit in adjuvant...
The first interim results of the Phase III ADAURA study evaluating adjuvant osimertinib in stage IB-IIIA EGFR-mutated non-small cell lung cancer (NSCLC) were presented at the plenary session during...
View ArticleFirst-line therapy with TKIs in NSCLC
Advances in treatment options for anaplastic lymphoma kinase (ALK+) non-small cell lung cancer (NSCLC) have improved patient outcomes considerably in the last few years. This article highlights some...
View ArticleHead and neck cancer updates presented at ESMO 2020
EPIC-OPC study: misclassification of OPC patients The presence of human papillomavirus p16 alone is not sufficient to classify oropharyngeal cancer (OPC) as HPV-positive,1 therefore, it is important...
View ArticleRxPONDER: sparing chemotherapy in post-menopausal patients with node-positive...
The de-escalation and treatment personalization of patients with early breast cancer has advanced in recent years, with studies such as TAILORx (NCT00310180) demonstrating adjuvant endocrine therapy...
View ArticleEffect of fecal microbiota transplantation on anti-PD-1 resistant metastatic...
Advanced melanoma is an aggressive skin cancer characterized by poor survival and poor response to systemic cytotoxic chemotherapy. The use of anti-PD-1 immune checkpoint blockade molecules such as...
View ArticleAccelerating the pace from bench to beside: the NIHR Oncology Translational...
In a nationwide effort to prioritize and accelerate translational research, a brand-new oncology research collaboration has been established by The National Institute for Health Research (NIHR),...
View ArticleDostarlimab subject to accelerated FDA approval for the treatment of advanced...
The Food and Drug Administration (FDA) granted accelerated approval to dostarlimab on April 2021 for patients with recurrent or advanced deficient mismatch repair (dMMR) endometrial cancer that have...
View ArticleFDA approves mobocertinib for NSCLC with EGFR exon 20 insertion mutations
The U.S. Food and Drug Administration (FDA) has granted accelerated approval of mobocertinib for patients with metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor...
View ArticleFDA grants priority review for fixed-dose relatlimab plus nivolumab in...
The U.S Food and Drug Administration (FDA) has granted priority review for the fixed-dose combination of relatlimab, a LAG-3 targeting antibody, plus nivolumab based on the findings from...
View ArticlePHS290: a novel scoring algorithm provides a promising approach to screening...
A novel polygenic hazard score (PHS), PHS290, accurately predicts lifetime risks of developing metastatic or terminal prostate cancer across multiple ancestries, providing the potential to improve...
View Article177Lu-PSMA-617 approved for use in patients with PSMA+ mCRPC
As of the 23rd March 2022, the U.S. Food and Drug Administration (FDA) has approved 177Lu-PSMA-617 (a.k.a. Lu 177 Vipivotide Tetraxetan) as a radioligand therapy for previously-treated patients with...
View ArticleMOUNTAINEER: Tucatinib plus trastuzumab demonstrates good efficacy for the...
In the U.S., colorectal cancer (CRC) is the third leading cause of cancer-related deaths and is expected to lead to approximately 52,580 deaths in 2022.[1] Human epidermal growth factor receptor 2...
View ArticleEV-103 Cohort K: Promising data for first-line combination therapy of...
EV-103 (NCT03288545) is a multicohort study investigating the use of the antibody-drug conjugate, enfortumab vedotin, alone or in combination with other therapies for patients with urothelial...
View ArticleNew research elucidates how air pollution causes lung cancer in never-smokers
Research presented at the European Society of Medical Oncology (ESMO) Congress 2022 has uncovered a non-mutagenic mechanism by which air pollution promotes the development of lung cancer in people who...
View ArticleTROPiCS-02: Overall survival benefit of sacituzumab govitecan in HR+/HER2-...
Antibody-drug conjugates (ADCs) are an emerging class of anticancer drugs consisting of a monoclonal antibody linked to a cytotoxic chemotherapy payload, enabling a targeted therapeutic response....
View ArticleFirst-line maintenance with olaparib monotherapy and in combination...
Over 75% of patients with ovarian cancer are diagnosed at an advanced stage, as early-stage disease is usually asymptomatic.1,2 The prognosis of patients with advanced ovarian cancer is very poor, and...
View ArticleWorse outcomes for immunosuppressed patients with cancer and COVID-19 treated...
A report published in JAMA Oncology suggests that cancer patients with baseline immunosuppression and COVID-19 experience worse outcomes and an increased incidence of cytokine storm when treated with...
View ArticleEMERALD: updated results on the impact of duration of prior CDK4/6i and FDA...
The U.S. Food and Drug Administration (FDA) has granted priority review for elacestrant, a selective estrogen receptor degrader (SERD), based on findings from the Phase III EMERALD trial...
View ArticleFDA approves combination therapy of tremelimumab, durvalumab, and...
The U.S. Food and Drug Administration (FDA) have approved tremelimumab in combination with durvalumab and platinum-based chemotherapy for metastatic non-small cell lung cancer (NSCLC) patients with no...
View ArticleTrastuzumab deruxtecan and the evolving HER2-low breast cancer landscape
VJOncology is excited to present the latest data and developments in the HER2-low breast cancer field, with comments from experts Paolo Tarantino, Mattia Rediti, and Rani Bansal. Practice-changing...
View ArticleFDA approves atezolizumab for unresectable or metastatic alveolar soft part...
On December 9th 2022, The US Food and Drug Administration (FDA) permitted the approval of atezolizumab for adult and pediatric patients 2 years of age and older with unresectable or metastatic...
View ArticleManaging urothelial carcinoma with targeted therapies
VJOncology is excited to present the latest data and developments in the bladder cancer field, with comments from Yohann Loriot, Jonathan Rosenberg, Petros Grivas and more. In the last four years, FDA...
View ArticleSPOTLIGHT: zolbetuximab plus chemotherapy prolongs PFS and OS in CLDN18.2+...
Primary results from the Phase III SPOTLIGHT (NCT03504397) trial demonstrated a significant survival benefit for patients with Claudin18.2 (CLDN18.2)-positive, HER2-negative, locally advanced...
View ArticleBWEL: a phone-based weight loss intervention in early-stage breast cancer
Initial data from the Phase III Breast Cancer Weight Loss Study (BWEL) (NCT02750826) has shown promising results for a telephone-based weight loss intervention program (WLI) in overweight and obese...
View ArticleSIENDO: long-term PFS findings of maintenance selinexor in TP53wt endometrial...
Endometrial cancer is the most common gynecological cancer, where approximately 417,000 cases and 100,000 deaths were reported worldwide in 2020.1 The incidence of endometrial cancer has additionally...
View ArticleEV-302/KEYNOTE-A39: combination enfortumab vedotin and pembrolizumab improves...
The Phase III EV-302/KEYNOTE-A39 (NCT04223856) trial demonstrated that the combination of enfortumab vedotin and pembrolizumab significantly improved overall survival (OS) and progression-free...
View ArticleFDA approves pembrolizumab in combination with chemoradiotherapy for cervical...
Cervical cancer remains a significant global health concern, particularly affecting women in resource-limited settings. According to the World Health Organization (WHO), cervical cancer is the fourth...
View ArticleFDA approves osimertinib with platinum-based chemotherapy in EGFR-mutated NSCLC
Lung cancer accounts for approximately one in ten cases of cancer, with non-small cell lung cancer (NSCLC) accounting for a substantial portion of cases.1 Targeted therapies have played a significant...
View ArticleNADINA trial establishes new standard in stage III melanoma treatment:...
The NADINA trial (NCT04949113) marks a significant milestone in melanoma treatment, representing the first Phase III trial to compare neoadjuvant immunotherapy with the standard adjuvant approach and...
View Article